DEPOSIT AGREEMENT by and among RADIOPHARM THERANOSTICS LIMITED as Issuer, DEUTSCHE BANK TRUST COMPANY AMERICAS as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ISSUED...Deposit Agreement • July 25th, 2024 • Radiopharm Theranostics LTD • Pharmaceutical preparations • New York
Contract Type FiledJuly 25th, 2024 Company Industry JurisdictionDEPOSIT AGREEMENT, dated as of , 2024, by and among (i) Radiopharm Theranostics Limited, a company incorporated in the Commonwealth of Australia, with its principal executive office at 62 Lygon Street, Level 3, Carlton, Victoria, 3053, Australia (together with its successors, the “Company”), (ii) Deutsche Bank Trust Company Americas, an indirect wholly owned subsidiary of Deutsche Bank A.G., acting in its capacity as depositary, with its principal office at 1 Columbus Circle, New York, NY 10019, United States of America (the “Depositary”, which term shall include any successor depositary hereunder) and (iii) all Holders and Beneficial Owners of American Depositary Shares evidenced by American Depositary Receipts issued hereunder (all such capitalized terms as hereinafter defined).
Share subscription agreement Dated PartiesShare Subscription Agreement • July 25th, 2024 • Radiopharm Theranostics LTD • Pharmaceutical preparations
Contract Type FiledJuly 25th, 2024 Company IndustrySubscriber Lantheus Omega, LLC, a wholly-owned subsidiary of Lantheus Holdings, Inc. CIK 0001521036 of 201 Burlington Road, South Building, Bedford, MA, 01730
Purchase AND DEVELOPMENT AGREEMENTPurchase and Development Agreement • July 25th, 2024 • Radiopharm Theranostics LTD • Pharmaceutical preparations • Delaware
Contract Type FiledJuly 25th, 2024 Company Industry JurisdictionTHIS PURCHASE AND DEVELOPMENT AGREEMENT (this “Agreement”), dated as of May 23, 2024, is entered into by and between (i) Lantheus Omega, LLC a Delaware limited liability company (“Purchaser”) and wholly owned subsidiary of Lantheus Holdings, Inc., and (ii) Radiopharm Theranostics Limited, an Australian public company, and Radiopharm Theranostics (USA), Inc., a Nevada corporation (each, a “Seller” and collectively, the “Sellers”). Purchaser and Sellers are, from time to time, referred to individually herein as a “Party,” and collectively as the “Parties.”